Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.89
+3.9%		$1.15
$0.81
▼
$3.32
$236.04M0.264.16 million shs9.84 million shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$7.98
+12.7%		$17.08
$2.96
▼
$40.37
$411.62M0.5411.44 million shs8.44 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$17.34
+0.5%		$18.30
$7.78
▼
$34.10
$253.35M1.46123,086 shs111,627 shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$12.12
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+3.94%-0.87%-30.83%-13.20%-70.88%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+12.71%+90.45%-59.08%-73.02%+4.04%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.46%+2.48%+23.24%-36.23%+51.18%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%-6.23%-6.80%+0.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$0.89
+3.9%		$1.15
$0.81
▼
$3.32
$236.04M0.264.16 million shs9.84 million shs
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$7.98
+12.7%		$17.08
$2.96
▼
$40.37
$411.62M0.5411.44 million shs8.44 million shs
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$17.34
+0.5%		$18.30
$7.78
▼
$34.10
$253.35M1.46123,086 shs111,627 shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$12.12
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+3.94%-0.87%-30.83%-13.20%-70.88%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+12.71%+90.45%-59.08%-73.02%+4.04%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.46%+2.48%+23.24%-36.23%+51.18%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%-6.23%-6.80%+0.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.33
Hold$3.75323.54% Upside
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
2.00
Hold$29.15265.29% Upside
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.00
Hold$69.00297.92% Upside
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest KVAC, GLSI, AKBA, and CAPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Overweight
8/12/2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$1.00
8/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/3/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/31/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Neutral$2.00
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Neutral$3.50
7/30/2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
LADENBURG THALM/SH SH logo
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$219.06M1.12N/AN/A$0.09 per share9.84
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M20.83N/AN/A$4.24 per share1.88
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.21 per shareN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.11N/AN/AN/A-13.54%-88.88%-7.74%N/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$105.04M-$2.45N/AN/AN/AN/A-56.60%-43.97%N/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$19.36M-$1.54N/AN/AN/AN/A-793.81%-295.32%N/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest KVAC, GLSI, AKBA, and CAPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.5889-$0.70-$0.1111-$0.70$2.08 millionN/A
8/14/2026Q2 2026
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A$0.08N/A$0.08N/AN/A
8/11/2026Q2 2026
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.33-$0.27+$0.06-$0.27N/AN/A
8/5/2026Q2 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.0420-$0.02+$0.0220-$0.03$48.85 million$49.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
0.99
1.43
1.35
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
7.35
8.42
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.54
1.54
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
51.72%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
9.20%
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.47%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
80.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430277.11 million265.19 millionOptionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10158.14 million52.58 millionOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
314.68 million7.12 millionNot Optionable
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A5.51 million1.09 millionNot Optionable

Recent News About These Companies

Short Interest in Keen Vision Acquisition Corporation (NASDAQ:KVAC) Grows By 1,480.3%
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-keen-vision-acquisition-corporation-nasdaqkvac-grows-by-14803-2026-08-11/
Keen Vision Extends Timeline for Business Combination Deal
July 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-extends-timeline-for-business-combination-deal?utm_source=marketbeat.com&utm_medium=referral
Berkley W R Corp Sells 649,375 Shares of Keen Vision Acquisition Corporation $KVAC
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-berkley-w-r-corp-sells-649375-shares-of-keen-vision-acquisition-corporation-kvac-2026-07-27/
Keen Vision Acquisition (NASDAQ:KVAC) Shares Down 1% - Should You Sell?
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/keen-vision-acquisition-nasdaqkvac-shares-down-1-should-you-sell-2026-07-22/
Keen Vision Acquisition Extends SPAC Deadline with Sponsor Note
April 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-acquisition-extends-spac-deadline-with-sponsor-note?utm_source=marketbeat.com&utm_medium=referral
Keen Vision, Medera Extend Timeline for Revised Merger
April 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-medera-extend-timeline-for-revised-merger?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Signs New Letter of Intent with Novoheart
March 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-signs-new-letter-of-intent-with-novoheart?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Extends SPAC Timeline and Secures Funding
January 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-extends-spac-timeline-and-secures-funding?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Acquisition Extends Business Combination Deadline
January 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-acquisition-extends-business-combination-deadline?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Issues Promissory Note for Business Extension
November 24, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-issues-promissory-note-for-business-extension?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy?
November 22, 2025  |  defenseworld.netD
Keen Vision Extends Business Combination Deadline
September 25, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-extends-business-combination-deadline?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Transfers Funds to Trust Account
September 2, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-transfers-funds-to-trust-account?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Issues Promissory Note to Extend Merger Time
August 22, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-issues-promissory-note-to-extend-merger-time?utm_source=marketbeat.com&utm_medium=referral
KVAC Keen Vision Acquisition Corporation - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/KVAC
Keen Vision Issues Promissory Note to Extend Deadline
June 27, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/keen-vision-issues-promissory-note-to-extend-deadline?utm_source=marketbeat.com&utm_medium=referral
Keen Vision Acquisition Corporation (KVACW) - Yahoo Finance
June 27, 2025  |  au.finance.yahoo.comhttps://au.finance.yahoo.com/quote/KVACW/
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
June 13, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/13/3098965/0/en/medera-and-novoheart-presented-breakthroughs-in-human-mini-heart-platforms-and-gene-therapy-at-isscr-2025.html
Keen Vision Acquisition Corporation Ordinary Shares
June 6, 2025  |  fxempire.comF
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
May 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/12/3079073/0/en/medera-to-present-late-breaking-phase-1-2a-clinical-trial-results-at-heart-failure-2025-congress.html
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
April 1, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/01/3053271/0/en/medera-presented-updated-results-from-first-in-human-gene-therapy-trial-for-heart-failure-with-preserved-ejection-fraction-at-2025-hfpef-summit.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$0.89 +0.03 (+3.94%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$0.90 +0.01 (+1.08%)
As of 08/19/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$7.98 +0.90 (+12.71%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$8.00 +0.01 (+0.19%)
As of 08/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$17.34 +0.08 (+0.46%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$17.74 +0.40 (+2.28%)
As of 08/19/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Keen Vision Acquisition stock logo

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)
As of 08/18/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas